Ocular Therapeutix
This is a leadership role overseeing the quality control functions related to stability, data review, and sample management in a biopharmaceutical company. It involves strategic planning, team management, ensuring compliance with regulatory standards, and cross-functional collaboration to support manufacturing and regulatory processes.
Headquarters
Bedford, Massachusetts, United States
Company Size
51-200 employees
Founded
2006
Ocular Therapeutix is an ophthalmic biopharmaceutical company focused on developing innovative treatments for retinal diseases. Its lead program, AXPAXLI™, is a sustained‑release hydrogel therapy in development as a potential treatment for wet age‑related macular degeneration (wet AMD), designed to extend drug exposure and reduce injection frequency. The company develops and aims to commercialize ophthalmic products that improve outcomes for people with retinal disease. Ocular Therapeutix combines drug formulation and ocular drug‑delivery technology to redefine treatment approaches in retinal care.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Ocular Therapeutix.
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
Dec 8, 2025
Quality Control Stability Associate II
Moderna
Manager, Quality Control – Stability and Sample Management
Insmed Incorporated
Stability Operations Partner
City of Pierre, South Dakota
Stability Coordinator II
Integrated Resources INC
Senior Manager, Global Sample Stability and Retains Program
Arrowhead Pharmaceuticals
Stability Coordinator
Pine Pharmaceuticals